- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07944001
Effect of Quadro-Iliac Plane Block on Recovery After Laparoscopic Hysterectomy (QIPB-TLH)
Effect of Quadro-Iliac Plane Block on Postoperative Quality of Recovery in Patients Undergoing Laparoscopic Hysterectomy: A Prospective, Randomized, Controlled Clinical Trial
This prospective, randomized, controlled clinical trial aims to evaluate the effect of an ultrasound-guided bilateral quadro-iliac plane block (QIPB) on postoperative recovery quality in patients undergoing elective total laparoscopic hysterectomy.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Total laparoscopic hysterectomy (TLH) is a minimally invasive surgical procedure; however, patients may experience postoperative pain originating from abdominal incisions, visceral manipulation, and pneumoperitoneum-related irritation. Inadequate postoperative pain management may negatively affect patient comfort, early mobilization, and overall quality of recovery. Although opioids provide effective analgesia, their use may be associated with nausea, vomiting, sedation, and other adverse effects. Therefore, multimodal and opioid-sparing analgesic strategies are important components of perioperative care.
The quadro-iliac plane block (QIPB) is an ultrasound-guided fascial plane block targeting the anatomical plane near the caudal attachment of the quadratus lumborum muscle to the iliac crest. Previous clinical studies have suggested that QIPB may improve postoperative analgesia and reduce opioid requirements in selected surgical populations. However, its effect on postoperative recovery quality following total laparoscopic hysterectomy remains to be investigated.
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Betül Kozanhan, M.D
- Numer telefonu: 0 (332) 310 50 00
- E-mail: betulkozanhan@gmail.com
Lokalizacje studiów
-
-
-
Konya, Turcja (Türkiye)
- Betul Kozanhan
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Female patients aged 18 years or older.
- Scheduled for elective total laparoscopic hysterectomy.
- American Society of Anesthesiologists (ASA) physical status I-III.
- Body weight of at least 55 kg.
- Ability to communicate in Turkish and reliably complete the Turkish version of the Quality of Recovery-15 questionnaire (QoR-15T).
- Provision of written informed consent after receiving information about the study.
Exclusion Criteria:
- Refusal to provide informed consent or withdrawal of consent.
- Any contraindication to regional anesthesia.
- Infection at the intended block site or anatomical conditions preventing safe needle insertion.
- Severe hypersensitivity or contraindication to local anesthetics or standard/rescue analgesic medications specified in the study protocol.
- Regular opioid use or opioid use disorder.
- Regular analgesic use for chronic pain lasting longer than three months.
- Clinically significant hepatic or renal insufficiency.
- Pregnancy, postpartum period, or breastfeeding.
- Cognitive or communication impairment preventing reliable completion of QoR-15T or postoperative pain assessments.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: QIPB Group
Patients will receive bilateral ultrasound-guided quadro-iliac plane blocks with 20 mL of 0.25% bupivacaine per side in addition to standard multimodal analgesia. |
After surgery and before extubation, bilateral QIPB will be performed under ultrasound guidance. A total of 40 mL of 0.25% bupivacaine (20 mL per side) will be injected into the quadro-iliac fascial plane.
Inne nazwy:
|
|
Brak interwencji: Control Group
Patients will receive standard general anesthesia and postoperative multimodal analgesia without a regional block. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Quality of Postoperative Recovery Assessed by the QoR-15T Score
Ramy czasowe: 24 hours postoperatively
|
Postoperative quality of recovery will be assessed using the validated Turkish version of the 15-item Quality of Recovery questionnaire (QoR-15T). The questionnaire consists of 15 items, each scored from 0 to 10, yielding a total score ranging from 0 to 150. Higher scores indicate better quality of recovery. The primary outcome is the total QoR-15T score at 24 hours postoperatively, compared between the bilateral Quadro-Iliac Plane Block (QIPB) group and the control group. |
24 hours postoperatively
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Postoperative Pain Intensity at Rest
Ramy czasowe: PACU admission and 2, 4, 6, 8, 12, and 24 hours postoperatively
|
Postoperative pain intensity at rest will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. |
PACU admission and 2, 4, 6, 8, 12, and 24 hours postoperatively
|
|
Postoperative Pain Intensity During Movement or Coughing
Ramy czasowe: PACU admission and 2, 4, 6, 8, 12, and 24 hours postoperatively
|
Postoperative pain intensity during movement or coughing will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. |
PACU admission and 2, 4, 6, 8, 12, and 24 hours postoperatively
|
|
Time to First Rescue Analgesia
Ramy czasowe: Within 24 hours postoperatively
|
Time from admission to the post-anesthesia care unit (PACU) to the first administration of rescue analgesia will be recorded in minutes. |
Within 24 hours postoperatively
|
|
Time to First Opioid Analgesia
Ramy czasowe: Within 24 hours postoperatively
|
Time from admission to the post-anesthesia care unit (PACU) to the first administration of intravenous opioid will be recorded in minutes. |
Within 24 hours postoperatively
|
|
Total Postoperative Tramadol Consumption
Ramy czasowe: First 24 hours postoperatively
|
The total cumulative dose of intravenous opioid administered during the first 24 hours after surgery will be recorded. |
First 24 hours postoperatively
|
|
Postoperative Nausea and Vomiting
Ramy czasowe: Within 24 hours postoperatively
|
Postoperative nausea and vomiting (PONV) will be assessed using a 5-point Verbal Descriptive Scale (VDS), ranging from 0 to 4 (0 = no nausea or vomiting, 1 = mild nausea, 2 = moderate nausea or vomiting, 3 = frequent vomiting, and 4 = severe vomiting). Higher scores indicate more severe symptoms. |
Within 24 hours postoperatively
|
|
Patient Satisfaction with Postoperative Analgesia
Ramy czasowe: 24 hours postoperatively
|
Patient satisfaction with postoperative pain management will be assessed at 24 hours after surgery using a 5-point Likert scale ranging from 1 to 5. Higher scores indicate greater patient satisfaction with postoperative analgesia. |
24 hours postoperatively
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Inne numery identyfikacyjne badania
- KSH-QIPB-TLH-2026-01
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .